Leitlinie
EGFR Testing and the CAP/IASLC/AMP Lung Cancer Biomarker Testing Guidelines: Knowledge Gaps and Future Directions
Lung Cancer Management · 01.04.2015 · 4 (2) · 87-95
DOI: 10.2217/lmt.15.4 ↗Kurz gefasst
Leitlinie in der Zeitschrift Lung Cancer Management, online erschienen am 18.03.2015. Verfasst von Elena Vigliar und 3 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Vigliar, E., Malapelle, U., Bellevicine, C., & Troncone, G. (2015). EGFR Testing and the CAP/IASLC/AMP Lung Cancer Biomarker Testing Guidelines: Knowledge Gaps and Future Directions. Lung Cancer Management, 4(2), 87-95. https://doi.org/10.2217/lmt.15.4
Vancouver
Vigliar E, Malapelle U, Bellevicine C, Troncone G. EGFR Testing and the CAP/IASLC/AMP Lung Cancer Biomarker Testing Guidelines: Knowledge Gaps and Future Directions. Lung Cancer Management. 2015;4(2):87-95. doi:10.2217/lmt.15.4
BibTeX
@article{Vigliar2015,
author = {Vigliar, Elena and Malapelle, Umberto and Bellevicine, Claudio and Troncone, Giancarlo},
title = {EGFR Testing and the CAP/IASLC/AMP Lung Cancer Biomarker Testing Guidelines: Knowledge Gaps and Future Directions},
journal = {Lung Cancer Management},
year = {2015},
volume = {4},
number = {2},
pages = {87--95},
doi = {10.2217/lmt.15.4}
}
EUVIMED